HyperBio Therapeutics ApS: Financial statements 2021
CVR: 41244909
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
HyperBio Therapeutics ApS (CVR 41244909) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -12,881,904 and a net result of DKK -10,612,873. Equity in the 2021 report amounted to DKK 5,368,897. The solvency ratio was 23.5%.
- Gross Profit
- DKK -12,881,904
- Profit/Loss
- DKK -10,612,873
- Equity
- DKK 5,368,897
- Total Assets
- DKK 22,826,507
Official annual report
Find more companies like HyperBio Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
As of June 18, 2021, Niccolo' Bacchi-Bønnelykke has left the board of directors of HyperBio Therapeutics ApS.
HyperBio Therapeutics ApS has published its interim report for the period March 12, 2020 – December 31, 2020.
About HyperBio Therapeutics ApS
HyperBio Therapeutics ApS was a Danish company of the type Anpartsselskab based in Vejle Øst, founded in 2020. The company has been dissolved on 14 January 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2023, the company reported a gross profit of DKK -74,484 and a net result of DKK -972,747 compared with DKK -7,656,366 the year before. Equity in the 2023 report amounted to DKK 739,784.